Do all patients with acromegaly respond to Sandostatin® treatment?
Clinical studies show that Sandostatin® produces a fall in GH serum concentration in approximately 85-90% of patients with acromegaly.30,31 More than 50% of those treated will achieve serum GH levels (5 g/L and almost 75% of patients will have normalized IGF-1 levels.32 In a recent study in 42 patients with acromegaly, a single dose of Sandostatin® reduced GH levels from a mean basal level of 26 g/L to less than 5 g/L in 74% of patients within 6 hours.31 GH levels were suppressed by more than 45% in all but 7% of patients. Endocrinological response rates appear to improve with time during long-term Sandostatin® LAR® therapy. During a recent study, GH levels decreased significantly after 3 months’ treatment with Sandostatin® LAR® to 2.1 g/L after 2 years (p(0.05).33 Baseline GH levels are sometimes predictive of treatment outcome. Indeed, it has been reported that Sandostatin® normalizes GH levels most frequently when baseline GH levels are less than 35-50 g/L.34 Previous surgery/irradi
Related Questions
- Is it true that older patients in general respond more slowly to antidepressant treatment and that it takes at least 12 weeks to identify nonresponders?
- Does WIPHL cover the cost of treatment for patients who don respond to brief interventions?
- Do all patients with acromegaly respond to Sandostatin® treatment?
